Vironexis is a startup based in the United States, most recent round Series A.
Based in the United States, Vironexis is a startup. Its most recent tracked round is Series A.
Vironexis is a clinical-stage biotechnology company developing the first in vivo protein engineering platform using AAV gene therapy to enable continuous, off-the-shelf T-cell engager expression for cancer and immune disorder treatments.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.